Cardion is a pioneering biopharmaceutical company established in 1996. The company's primary focus is on developing cardiovascular gene therapy products by leveraging advanced gene delivery, stem cell engineering, and tolerance induction. Headquartered in Erkrath, Nordrhein-Westfalen, Cardion operates within the Biopharma and Biotechnology industries.
With a proven track record since its inception, Cardion secured a notable €11.50M Venture Round investment on 23 September 2002. The funding round was backed by a consortium of prominent investors including IKB Deutsche Industriebank, Deutsche Venture Capital, Mulligan BioCapital, ITX Corporation, Techno Venture Management, and Gold-Zack AG.
Cardion's longstanding presence in the field, coupled with its innovative approach to cardiovascular gene therapy, positions it as an intriguing prospect for venture capitalists seeking to invest in the biopharmaceutical sector.
